SLN Biopsy Predicts Lymph Node Status in Endometrial CALast Updated: April 12, 2011. Sentinel lymph node biopsy appears promising as a less invasive alternative to complete lymphadenectomy for diagnosing lymph node status in patients with early-stage endometrial cancer, according to research published online April 12 in The Lancet Oncology.
TUESDAY, April 12 (HealthDay News) -- Sentinel lymph node (SLN) biopsy appears promising as a less invasive alternative to complete lymphadenectomy for diagnosing lymph node status in patients with early-stage endometrial cancer, according to research published online April 12 in The Lancet Oncology.
Marcos Ballester, M.D., of Tenon University Hospital in Paris, and colleagues conducted SLN biopsy in 133 patients with stage I or II endometrial cancer to assess the detection rate and diagnostic accuracy of SLN for predicting lymph node status in this patient population.
The researchers found that the procedure was successful in 77 percent of right hemipelvis cases and 76 percent of left hemipelvis cases; the overall detection rate was 98 percent. There were no false negative cases recorded in 100 percent of hemipelvises. Using the patient as the unit of analysis, the SLN technique produced a negative predictive value of 97 percent and sensitivity of 84 percent. The researchers identified no complications during SLN biopsy.
"SLN biopsy with cervical dual labeling could be a trade-off between systematic lymphadenectomy and no dissection at all in patients with endometrial cancer of low or intermediate risk. Moreover, our study suggests that SLN biopsy could provide important data to tailor adjuvant therapy," the authors write.
|Previous: American Association for Cancer Research, April 2-6, 2011||Next: Future-Directed Therapy a New Option to Treat Depression|
Reader comments on this article are listed below. Review our comments policy.